Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?

Journal of Nuclear Medicine

Volumn 54, Issue 1, 2013, Pages 19-26

  Cook, Gary J R ^a   Yip, Connie ^b   Siddique, Muhammad ^a   Goh, Vicky ^a   Chicklore, Sugama ^b   Roy, Arunabha ^a   Marsden, Paul ^a   Ahmad, Shahreen ^b   Landau, David ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

18F FDG PET CT; Chemoradiotherapy; Non small cell lung cancer; Textural analysis

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUORODEOXYGLUCOSE F 18; VINCRISTINE; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; FEMALE; GLYCOLYSIS; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR VOLUME; IMAGE PROCESSING; LUNG TUMOR; METABOLISM; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SCINTISCANNING; SURVIVAL; TRANSPORT AT THE CELLULAR LEVEL; TREATMENT OUTCOME;

AGED; BIOLOGICAL TRANSPORT; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; GLYCOLYSIS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LUNG NEOPLASMS; MALE; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR BURDEN;

MLCS; MLOWN;

EID: 84872015239     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.107375     Document Type: Article

References (35)

1. Yoon DH, Baek S, Choi CM, et al. FDG-PET as a potential tool for selecting patients with advanced non-small cell lung cancer who may be spared maintenance therapy after first-line chemotherapy. Clin Cancer Res. 2011;17:5093-5100.
2. Shiraishi K, Nomori H, Ohba Y, et al. Repeat FDG-PET for predicting pathological tumor response and prognosis after neoadjuvant treatment in nonsmall cell lung cancer: comparison with computed tomography. Ann Thorac Cardiovasc Surg. 2010;16:394-400.
3. Rebollo-Aguirre AC, Ramos-Font C, Villegas Portero R, et al. Is FDG-PET suitable for evaluating neoadjuvant therapy in non-small cell lung cancer? Evidence with systematic review of the literature. J Surg Oncol. 2010;101:486-494.
4. 18F-FDG PET/CT for patients with advanced/metastatic nonsmall cell lung cancer. J Thorac Oncol. 2009;4:816-821.
5. Dooms C, Verbeken E, Stroobants S, et al. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography. J Clin Oncol. 2008;26:1128-1134.
6. 18F-FDG PET in patients with non-small cell lung cancer. J Nucl Med. 2007;48:1592-1598.
7. Mac Manus MP, Hicks RJ, Matthews JP, et al. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer. 2005;49:95-108. (Pubitemid 40798098)
8. 18F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2011;38:1628-1635.
9. 18F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeks. Eur J Cancer. 2012;48:68-74.
10. Memon AA, Weber B, Winterdahl M, et al. PET imaging of patients with nonsmall cell lung cancer employing an EGF receptor targeting drug as tracer. Br J Cancer. 2011;105:1850-1855.
11. 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy. AJR. 2012;198:75-82.
12. 18F]fluorodeoxyglucose PET-CT uptake in stage III patients with non-small cell lung cancer treated by concurrent chemoradiotherapy. Eur J Radiol. 2011;77:92-96.
13. Borst GR, Belderbos JS, Boellaard R, et al. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer. 2005;41:1533-1541. (Pubitemid 40981834)
14. Lee KH, Lee SH, Kim DW, et al. High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy. Clin Cancer Res. 2006;12:4232-4236.
15. 18F-FDG uptake as a predictor of patient outcome. J Nucl Med. 2008;49:1973-1979.
16. El Naqa I, Grigsby PW, Aptea A, et al. Exploring feature-based approaches in PET images for predicting cancer treatment outcomes. Pattern Recognit. 2009;42:1162-1171.
17. Yu H, Caldwell C, Mah K, et al. Automated radiation targeting in head-and-neck cancer using region-based texture analysis of PET and CT images. Int J Radiat Oncol Biol Phys. 2009;75:618-625.
18. Yu H, Caldwell C, Mah K, Mozeg D. Coregistered FDG PET/CT-based textural characterization of head and neck cancer for radiation treatment planning. IEEE Trans Med Imaging. 2009;28:374-383.
19. 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med. 2011;52:369-378.
20. van Velden FH, Cheebsumon P, Yaqub M, et al. Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies. Eur J Nucl Med Mol Imaging. 2011;38:1636-1647.
21. Vaidya M, Creach KM, Frye J, et al. Combined PET/CT image characteristics for radiotherapy tumor response in lung cancer. Radiother Oncol. 2012;102:239-245.
22. Amadasun M, King R. Textural features corresponding to textural properties. IEEE Trans Syst Man Cybern. 1989;19:1264-1274.
23. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) ed. of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2:706-714. (Pubitemid 47357522)
24. Schleyer PJ, Baker S, Barrington SF, et al. Establishment of acquisition and reconstruction parameters for a GE Discovery VCT PET-CT scanner. Eur J Nucl Med Mol Imaging. 2008;35:S340-S341.
25. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50:122S-150S.
26. Uto F, Shiba E, Onoue S, et al. Phantom study on radiotherapy planning using PET/CT-delineation of GTV by evaluating SUV. J Radiat Res (Tokyo). 2010;51:157-164.
27. 18F-FDG PET. J Nucl Med. 2012;53:693-700.
28. 18F-FDG PET during stereotactic body radiotherapy for stage I lung tumours cannot predict outcome: a pilot study. Eur J Nucl Med Mol Imaging. 2011;38:1059-1063.
29. Goh V, Ganeshan B, Nathan P, et al. Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. Radiology. 2011;261:165-171.
30. Ganeshan B, Skogen K, Pressney I, et al. Tumour heterogeneity in oesophageal cancer assessed by CT texture analysis: preliminary evidence of an association with tumour metabolism, stage, and survival. Clin Radiol. 2012;67:157-164.
31. Al-Kadi OS, Watson D. Texture analysis of aggressive and nonaggressive lung tumor CE CT images. IEEE Trans Biomed Eng. 2008;55:1822-1830. (Pubitemid 351871633)
32. Kido S, Kuriyama K, Higashiyama M, et al. Fractal analysis of internal and peripheral textures of small peripheral bronchogenic carcinomas in thin-section computed tomography: comparison of bronchioloalveolar cell carcinomas with non bronchioloalveolar cell carcinomas. J Comput Assist Tomogr. 2003;27:56-61. (Pubitemid 36139752)
33. Ganeshan B, Panayiotou E, Burnand K, et al. Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: a potential marker of survival. Eur Radiol. 2012;22:796-802.
34. Ganeshan B, Abaleke S, Young RC, et al. Texture analysis of non-small cell lung cancer on unenhanced computed tomography: initial evidence for a relationship with tumour glucose metabolism and stage. Cancer Imaging. 2010;10:137-143.
35. Ganeshan B, Goh V, Mandeville H, et al. CT of non-small cell lung cancer: Histopathological correlates for texture parameters. Radiology. In press.